Back to top
more

Medtronic (MDT)

(Real Time Quote from BATS)

$91.77 USD

91.77
2,806,120

-0.97 (-1.05%)

Updated Aug 12, 2025 03:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 41% (145 out of 245)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

QIAGEN Ships Test Kits to China for Detecting Coronavirus

by Zacks Equity Research

QIAGEN (QGEN) expands the molecular testing portfolio by shipping QIAstat-Dx Respiratory 2019-nCoV Panel to China for faster detection of coronavirus SARS-CoV-2.

Zacks Equity Research

Here's Why You Should Hold on to Teleflex (TFX) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Teleflex (TFX) on its strong segmental and international performance in Q4.

Zacks Equity Research

Stock Market News for Feb 19, 2020

by Zacks Equity Research

Benchmarks ended mixed on Tuesday, as investors weighed the impact of the novel Coronavirus on global manufacturing supply chains and economy.

Zacks Equity Research

Tandem Diabetes Hits New 52-Week High: What's Driving It?

by Zacks Equity Research

Tandem Diabetes (TNDM) is optimistic about maintaining growth momentum on several recent developments.

Zacks Equity Research

Medtronic (MDT) Q3 Earnings Top Estimates, Revenues Miss

by Zacks Equity Research

Medtronic (MDT) demonstrates better-than-expected Q3 performances at CER, backed by growth in all major business segments and geographies.

Zacks Equity Research

Medtronic Buys Digital Surgery, Boosts AI-Focus Surgical Care

by Zacks Equity Research

Medtronic (MDT) to integrate Digital Surgery's business within its Surgical Robotics arm, in turn augmenting the company's position in the field of surgical AI.

Urmimala Biswas headshot

Medical Products Stock Q4 Earnings on Feb 13: DXCM, LH & More

by Urmimala Biswas

Strong foothold in the emerging markets so far widely contributes to some of the industry players' Q4 results.

Zacks Equity Research

Medtronic (MDT) to Report Q3 Earnings: What's in Store?

by Zacks Equity Research

In the fiscal third quarter, Medtronic (MDT) is expected to have registered strong growth for TAVR across the United States, courtesy of its higher adoption by the low-risk patient population.

Zacks Equity Research

Here's Why You Should Retain Integer Holdings Stock for Now

by Zacks Equity Research

Integer Holdings (ITGR) continues to benefit from portfolio management, strong foothold in the broader MedTech space and rising Non-Medical sales. However, intense competition remains a woe.

Zacks Equity Research

ZBH or MDT: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

ZBH vs. MDT: Which Stock Is the Better Value Option?

Zacks Equity Research

Medical Products Stock Feb 6 Earnings Roster: BDX, CAH & More

by Zacks Equity Research

Despite the ongoing US-China trade war, increased focus on innovation is likely to have driven performance of medical products players' quarterly performance.

Zacks Equity Research

Medtronic (MDT) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

Medtronic (MDT) closed at $119.99 in the latest trading session, marking a +1.7% move from the prior day.

Zacks Equity Research

Medtronic's Cobalt, Crome Heart Devices Portfolio Gets CE Mark

by Zacks Equity Research

Medtronic's (MDT) next generation BlueSync-enabled implantable heart devices, which incorporate upgraded features, receive CE mark.

Zacks Equity Research

Medtronic (MDT) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

In the latest trading session, Medtronic (MDT) closed at $118.37, marking a -0.68% move from the previous day.

Urmimala Biswas headshot

Medical Products' Earnings Due on Jan 29: ALGN, HOLX & More

by Urmimala Biswas

A series of product launches despite the ongoing regulatory hurdles is likely to favor revenues in the medical products space this earnings season.

Urmimala Biswas headshot

New Alliances Aid Quest Diagnostics Despite Reimbursement Woes

by Urmimala Biswas

Quest Diagnostics (DGX) is currently concentrating on diagnostic information services arm and disciplined capital deployment.

Zacks Equity Research

Medtronic (MDT) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Medtronic (MDT) closed the most recent trading day at $120.97, moving -0.1% from the previous trading session.

Zacks Equity Research

New Product Suite Boosts Intersect ENT Despite Cost Concerns

by Zacks Equity Research

With respect to Intersect ENT's (XENT) Propel line, the PROPEL suite scores as the standard of care for polyp patients undergoing sinus surgery.

Zacks Equity Research

Zimmer Biomet Rides on Product Launches Despite Pricing Woes

by Zacks Equity Research

Zimmer Biomet's (ZBH) execution of its priority agenda including quality remediation, supply recovery efforts and product introductions looks impressive.

Zacks Equity Research

Medtronic (MDT) Gets FDA Nod for Micra AV to Treat AV Block

by Zacks Equity Research

Medtronic's (MDT) Micra AV cleared by the FDA for the treatment of AV block in patients eligible for pacemaker implantation.

Zacks Equity Research

Hill-Rom (HRC) Gains Ground on Global Expansion, New Menu

by Zacks Equity Research

Hill-Rom (HRC) is optimistic about its latest buyouts of Breathe Technologies and Voalte, mirroring its outstanding capital management strategy in turn.

Zacks Equity Research

ResMed Launches AirFit F30i CPAP Mask, Widens Client Base

by Zacks Equity Research

ResMed (RMD) launches its first tube-up, full-face CPAP mask, thus completing its full-face mask portfolio.

Zacks Equity Research

Cardiovascular Systems (CSII) Stock Hits New 52-Week High

by Zacks Equity Research

Cardiovascular Systems (CSII) is optimistic about maintaining its growth momentum on several recent developments.

Zacks Equity Research

IDEXX Launches Cytology Service to Upgrade Veterinary Care

by Zacks Equity Research

IDEXX (IDXX) upgrades veterinary care experience by launching a rapid digital cytology service, thus enabling the provision of faster results.

Zacks Equity Research

Medtronic (MDT) Hits 52-Week High, Can the Run Continue?

by Zacks Equity Research

Medtronic (MDT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.